About: Immunoinformatics-guided design of an epitope-based vaccine against severe acute respiratory syndrome coronavirus 2 spike glycoprotein

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Immunoinformatics-guided design of an epitope-based vaccine against severe acute respiratory syndrome coronavirus 2 spike glycoprotein Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Immunoinformatics-guided design of an epitope-based vaccine against severe acute respiratory syndrome coronavirus 2 spike glycoprotein
Creator	Saad, Ahmed Paul, A Rakib, Ahmed Almalki, F Almalki, Talha Chakraborty, S Chakraborty, Sagar Chowdhury, M Chowdhury, Taslima Emon, N Emon, Sajal Emran, Eva, Firzan Eva, T Hadda, Faisal Hadda, T Mily, S Mily, Taibi Mimi, Mimi, N Nainu, Arkajyoti Nainu, F Paul, Asif Sami, Jahan Sami, S Shahriar, A Shahriar, Abu Shil, S Shil, Sabrina Tareq, A Tareq, Uddin
source	Elsevier; Medline; PMC
abstract	AIMS: With a large number of fatalities, coronavirus disease-2019 (COVID-19) has greatly affected human health worldwide. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes COVID-19. The World Health Organization has declared a global pandemic of this contagious disease. Researchers across the world are collaborating in a quest for remedies to combat this deadly virus. It has recently been demonstrated that the spike glycoprotein (SGP) of SARS-CoV-2 is the mediator by which the virus enters host cells. MAIN METHODS: Our group comprehensibly analyzed the SGP of SARS-CoV-2 through multiple sequence analysis and a phylogenetic analysis. We predicted the strongest immunogenic epitopes of the SGP for both B cells and T cells. KEY FINDINGS: We focused on predicting peptides that would bind major histocompatibility complex class I. Two optimal epitopes were identified, WTAGAAAYY and GAAAYYVGY. They interact with the HLA-B*15:01 allele, which was further validated by molecular docking simulation. This study also found that the selected epitopes are able to be recognized in a large percentage of the world's population. Furthermore, we predicted CD4(+) T-cell epitopes and B-cell epitopes. SIGNIFICANCE: Our study provides a strong basis for designing vaccine candidates against SARS-CoV-2. However, laboratory work is required to validate our theoretical results, which would lay the foundation for the appropriate vaccine manufacturing and testing processes.
has issue date	2020-08-13(xsd:dateTime)
bibo:doi	10.1016/j.compbiomed.2020.103967
bibo:pmid	32828069
has license	no-cc
sha1sum (hex)	1769613748e203c9347447b9ef2830336f0ec47f
schema:url	https://doi.org/10.1016/j.compbiomed.2020.103967
resource representing a document's title	Immunoinformatics-guided design of an epitope-based vaccine against severe acute respiratory syndrome coronavirus 2 spike glycoprotein
has PubMed Central identifier	PMC7423576
has PubMed identifier	32828069
schema:publication	Comput Biol Med
resource representing a document's body	covid:1769613748e203c9347447b9ef2830336f0ec47f#body_text
is schema:about of	named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'Medicine' named entity 'Biology' named entity 'Journal' named entity 'vaccine' named entity 'epitope' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'vaccine' named entity 'T-cell' named entity 'vaccine' named entity 'virus' named entity 'neutralizing antibodies' named entity 'immunogenicity' named entity 'coronaviruses' named entity 'host cells' named entity 'SARS-CoV-2' named entity 'MHC' named entity 'preclinical' named entity 'epitopes' named entity 'SARS-CoV-2' named entity 'vaccine' named entity 'peptide' named entity 'epitope' named entity 'protein sequence' named entity 'protein sequences' named entity 'antigenicity' named entity 'T-cell' named entity 'T-cell' named entity 'Cytotoxic T cells' named entity 'ACE2' named entity 'protein' named entity 'immunogenic' named entity 'MHC' named entity '19, 20' named entity 'BLASTp' named entity 'MHC class II' named entity 'epitope' named entity 'peptide' named entity 'viral infections' named entity 'Clustal' named entity 'MSA' named entity 'experimental design' named entity 'animal model' named entity 'epitopes' named entity 'alleles' named entity 'BLASTp' named entity 'homologs' named entity 'Allergenicity' named entity 'epitope' named entity 'B-cell' named entity 'antibody response'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software